Profund Advisors LLC Has $1.58 Million Stake in Exact Sciences Co. (NASDAQ:EXAS)

Profund Advisors LLC trimmed its stake in Exact Sciences Co. (NASDAQ:EXAS) by 15.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 16,796 shares of the medical research company’s stock after selling 3,150 shares during the period. Profund Advisors LLC’s holdings in Exact Sciences were worth $1,577,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of EXAS. American Century Companies Inc. grew its position in Exact Sciences by 16.5% in the 1st quarter. American Century Companies Inc. now owns 5,760 shares of the medical research company’s stock worth $403,000 after purchasing an additional 817 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in Exact Sciences in the 1st quarter worth $742,000. Panagora Asset Management Inc. grew its position in Exact Sciences by 4.6% in the 1st quarter. Panagora Asset Management Inc. now owns 7,281 shares of the medical research company’s stock worth $509,000 after purchasing an additional 323 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Exact Sciences by 13.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 448,640 shares of the medical research company’s stock worth $31,377,000 after purchasing an additional 53,454 shares during the last quarter. Finally, Vontobel Holding Ltd. grew its position in Exact Sciences by 143.5% in the 1st quarter. Vontobel Holding Ltd. now owns 22,230 shares of the medical research company’s stock worth $1,585,000 after purchasing an additional 13,102 shares during the last quarter. 89.13% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Trading Up 1.5 %

Shares of NASDAQ EXAS opened at $67.29 on Tuesday. Exact Sciences Co. has a 1-year low of $40.73 and a 1-year high of $100.77. The company has a market cap of $12.17 billion, a PE ratio of -42.32 and a beta of 1.46. The company has a current ratio of 2.41, a quick ratio of 2.13 and a debt-to-equity ratio of 0.74. The company has a 50-day moving average of $66.20 and a two-hundred day moving average of $79.81.

Analyst Upgrades and Downgrades

EXAS has been the topic of several recent research reports. StockNews.com initiated coverage on shares of Exact Sciences in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Robert W. Baird lifted their target price on shares of Exact Sciences from $99.00 to $121.00 and gave the company an “outperform” rating in a research report on Wednesday, August 2nd. The Goldman Sachs Group decreased their target price on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Benchmark lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Bank of America lifted their target price on shares of Exact Sciences from $105.00 to $110.00 in a research report on Wednesday, August 2nd. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Exact Sciences has an average rating of “Moderate Buy” and a consensus target price of $96.56.

Insiders Place Their Bets

In other Exact Sciences news, insider Everett Cunningham sold 13,007 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $66.49, for a total value of $864,835.43. Following the completion of the transaction, the insider now directly owns 37,909 shares of the company’s stock, valued at $2,520,569.41. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.